Fortress Biotech Statistics
Want to see FBIO full AI Analyst Report?
Fortress Biotech (FBIO) Stock Statistics & Valuation Metrics
Total Valuation
Fortress Biotech has a market cap or net worth of $62.70M. The enterprise value is -$23.99M.
- Market Cap
- $62.70M
- Enterprise Value
- -$23.99M
Share Statistics
Fortress Biotech has 33,350,994 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 33,350,994
- Owned by Insiders
- 27.59%
- Owned by Institutions
- 10.41%
Financial Efficiency
Fortress Biotech’s return on equity (ROE) is 0.14 and return on invested capital (ROIC) is -49.97%.
- Return on Equity (ROE)
- 0.14
- Return on Assets (ROA)
- 0.04
- Return on Invested Capital (ROIC)
- -49.97%
- Return on Capital Employed (ROCE)
- -0.52
- Revenue Per Employee
- 811.05K
- Profits Per Employee
- 87.37K
- Employee Count
- 78
- Asset Turnover
- 0.34
- Inventory Turnover
- 2.17
Valuation Ratios
The current PE Ratio of Fortress Biotech is 0.65. Fortress Biotech’s PEG ratio is 0.00.
- PE Ratio
- 0.65
- PS Ratio
- 0.90
- PB Ratio
- 0.40
- Price to FCF
- 0.50
- Price to Operating Cash Flow
- 0.50
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Fortress Biotech had revenue of 63.26M and earned 6.82M in profits. Earnings per share was -0.07.
- Revenue
- 63.26M
- Gross Profit
- 42.34M
- Operating Income
- -70.22M
- Pretax Income
- -33.53M
- Net Income
- 6.82M
- EBITDA
- -20.16M
- Earnings Per Share (EPS)
- -0.07
Cash Flow
In the last 12 months, operating cash flow was 125.83M and capital expenditures -86,000, giving a free cash flow of 125.75M billion.
- Operating Cash Flow
- 125.83M
- Free Cash Flow
- 125.75M
- Free Cash Flow per Share
- 3.73
Dividends & Yields
Fortress Biotech pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 200.55%
- Earnings Yield
- 157.81%
Stock Price Statistics
- Beta
- 0.87
- 52-Week Price Change
- -24.50%
- 50-Day Moving Average
- 2.14
- 200-Day Moving Average
- 2.71
- Relative Strength Index (RSI)
- 42.47
- Average Volume (3m)
- 286.61K
Important Dates
Fortress Biotech upcoming earnings date is Apr 01, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 13, 2026
- Next Earnings Date
- Apr 01, 2027
- Ex-Dividend Date
- ―
Financial Position
Fortress Biotech as a current ratio of 2.49, with Debt / Equity ratio of 148.98%
- Current Ratio
- 2.49
- Quick Ratio
- 2.30
- Debt to Market Cap
- 0.58
- Net Debt to EBITDA
- 0.25
- Interest Coverage Ratio
- -8.06
Taxes
In the past 12 months, Fortress Biotech has paid -620.00K in taxes.
- Income Tax
- -620.00K
- Effective Tax Rate
- 0.02
Enterprise Valuation
Fortress Biotech EV to EBITDA ratio is -0.35, with an EV/FCF ratio of -0.40.
- EV to Sales
- -0.72
- EV to EBITDA
- -0.35
- EV to Free Cash Flow
- -0.40
- EV to Operating Cash Flow
- -0.40
Balance Sheet
Fortress Biotech has $152.19M in cash and marketable securities with $38.95M in debt, giving a net cash position of $113.23M billion.
- Cash & Marketable Securities
- $152.19M
- Total Debt
- $38.95M
- Net Cash
- $113.23M
- Net Cash Per Share
- $3.40
- Tangible Book Value Per Share
- $4.52
Margins
Gross margin is 63.17%, with operating margin of -42.47%, and net profit margin of 143.05%.
- Gross Margin
- 63.17%
- Operating Margin
- -42.47%
- Pretax Margin
- 183.83%
- Net Profit Margin
- 143.05%
- EBITDA Margin
- 203.89%
- EBIT Margin
- 196.76%
Analyst Forecast
The average price target for Fortress Biotech is $5.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $5.00
- Price Target Upside
- 165.96% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- 12.34%
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 6
- AI Score
- 64

